Page 1248 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1210 ParT TEN Prevention and Therapy of Immunological Diseases

blisibimod (AMG 623/A-623): results from randomized, double-blind 85. Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group.
phase 1a and phase 1b trials. Arthritis Res Ther 2015;17:215. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N
69. Tocoian A, Buchan P, Kirby H, et al. First-in-human trial of the safety, Engl J Med 2010;363(3):221.
pharmacokinetics and immunogenicity of a PEGylated anti-CD40L 86. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of
antibody fragment (CDP7657) in healthy individuals and patients with rituximab for the treatment of severe cryoglobulinemic vasculitis.
systemic lupus erythematosus. Lupus 2015;24(10):1045–56. Arthritis Rheum 2012;64(3):843–53.
70. Brennan DC, Daller JA, Lake KD, et al. Thymoglobulin Induction Study 87. Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use
Group Rabbit antithymocyte globulin versus basiliximab in renal of rituximab in refractory lupus: data from the Italian Multicentre
transplantation. N Engl J Med 2006;355(19):1967. Registry. Clin Exp Rheumatol 2015;33(4):449–56.
71. Zou J, Li T, Huang X, et al. Basiliximab may improve the survival rate of 88. Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary
rapidly progressive interstitial pneumonia in patients with clinically Sjögren’s syndrome. Scand J Immunol 2008;68(6):554–64.
amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum 89. Reed AM, Crowson CS, Hein M, et al; RIM Study Group. Biologic
Dis 2014;73(8):1591–3. predictors of clinical improvement in rituximab-treated refractory
72. Becker MO, Brückner C, Scherer HU, et al. The monoclonal anti-CD25 myositis. BMC Musculoskelet Disord 2015;16:257.
antibody basiliximab for the treatment of progressive systemic sclerosis: 90. Querol L, Rojas-García R, Diaz-Manera J, et al. Rituximab in
an open-label study. Ann Rheum Dis 2011;70(7):1340–1. treatment-resistant CIDP with antibodies against paranodal proteins.
73. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Neurol Neuroimmunol Neuroinflamm 2015;2(5):e149.
Database Syst Rev 2009;(4):CD007277. 91. Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis.
74. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term Autoimmun Rev 2016;15(7):714–18.
outcomes in kidney transplantation. N Engl J Med 2016;374(4):333–43. 92. Wang HH, Liu CW, Li YC, et al. Efficacy of rituximab for pemphigus: a
75. Easthope S, Jarvis B. Omalizumab. Drugs 2001;61(2):253. systematic review and meta-analysis of different regimens. Acta Derm
76. Jachiet M, Samson M, Cottin V, et al; French Vasculitis Study Group Venereol 2015;95(8):928–32.
(FVSG). Anti-IgE monoclonal antibody (omalizumab) in refractory and 93. Kado R, Sanders G, McCune WJ. Suppression of normal immune
relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): responses after treatment with rituximab. Curr Opin Rheumatol
data from 17 patients. Arthritis Rheumatol 2016;68(9):2274–82. 2016;28(3):251–8.
77. Oliver JM, Tarleton CA, Gilmartin L, et al. Reduced FcεRI-mediated 94. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated
release of asthma-promoting cytokines and chemokines from human progressive multifocal leucoencephalopathy in patients treated with
basophils during omalizumab therapy. Int Arch Allergy Immunol rituximab, natalizumab, and efalizumab: a Review from the Research on
2010;151:275. Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol
78. Ortega HG, Liu MC, Pavord ID, et al; MENSA Investigators. 2009;10(8):816–24.
Mepolizumab treatment in patients with severe eosinophilic asthma. N 95. Pawluczkowycz AW, et al. Binding of submaximal C1q promotes
Engl J Med 2014;371(13):1198–207. complement-dependent cytotoxicity (CDC) of B cells opsonized with
79. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably
controlled asthma with elevated blood eosinophil counts: results from higher levels of CDC are induced by OFA than by RTX. J Immunol
two multicentre, parallel, double-blind, randomised, placebo-controlled, 2009;183:749–58.
phase 3 trials. Lancet Respir Med 2015;3(5):355–66. 96. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II,
80. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic
airway eosinophils in asthmatic patients with sputum eosinophilia. J lymphocytic leukemia whole blood assays in comparison with rituximab
Allergy Clin Immunol 2013;132(5):1086–96. and alemtuzumab. J Immunol 2011;186(6):3762–9.
81. Mélet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell 97. Keith MP, Pitchford C, Bernstein WB. Treatment of hemophagocytic
depletion in patients with rheumatoid arthritis: association with clinical lymphohistiocytosis with alemtuzumab in systemic lupus
response. Arthritis Rheum 2013;65(11):2783–90. erythematosus. J Clin Rheumatol 2012;18(3):134–7.
82. Alunno A, Carubbi F, Bistoni O, et al. Interleukin (IL)-17-producing 98. Mohammad AJ, Smith RM, Chow YW, et al. Alemtuzumab as Remission
pathogenic T lymphocytes co-express CD20 and are depleted by Induction Therapy in Behçet Disease: A 20-year Experience. J
rituximab in primary Sjögren’s syndrome: a pilot study. Clin Exp Rheumatol 2015;42(10):1906–13.
Immunol 2016;184(3):284–92. 99. Jones JL, Coles AJ. Mode of action and clinical studies with
83. Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab alemtuzumab. Exp Neurol 2014;262(Pt A):37–43.
for rheumatoid arthritis. Cochrane Database Syst Rev 100. Cabrera CM, Urra JM, Carreño A, et al. Differential expression of CD30
2015;(1):CD007356. on CD3 T lymphocytes in patients with systemic lupus erythematosus.
84. Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation Scand J Immunol 2013;78(3):306–12.
biomarkers as predictive factors for the response to rituximab in
rheumatoid arthritis: a six-month, national, multicenter, open-label
study. Arthritis Rheum 2011;63(4):933–8.